1.Fertility sparing surgery in patients with early stage epithelial ovarian cancer: implication of survival analysis and lymphadenectomy.
Journal of Gynecologic Oncology 2014;25(4):270-271
No abstract available.
Female
;
Fertility Preservation/*methods
;
Humans
;
Neoplasms, Glandular and Epithelial/*surgery
;
Ovarian Neoplasms/*surgery
;
Pregnancy
2.A Case of Radiation-Induced Enteritis Effectively Treated with Daikenchuto
Kampo Medicine 2018;69(2):173-177
Radiation-induced enteritis can cause acute or chronic radiation damage to bowel tissues producing a variety of symptoms which can have a significant impact on patients' quality of life. The herbal medicine, daikenchuto has been noted for its usefulness in preventing postoperative ileus or abdominal dysfunction. Here, we present a case of radiation-induced enteritis ; a 59-year-old woman who underwent radical hysterectomy and subsequent chemoradiotherapy for cervical cancer. Daikenchuto (TJ-100, Tsumura, Japan, 15 g/day) was administered to the patient in hopes of controlling abdominal dysfunction, pain, and fullness that was considered as a series of symptoms of radiation-induced enteritis. This case was successfully treated with daikenchuto in an attempt to control and prevent these gastrointestinal symptoms associated with radiation-induced enteritis. An increase in bloodstream with daikenchuto to the intestinal tract in which a microcirculatory insufficiency was developed by radiation exposure, may contribute to the improvement of these abdominal symptoms of this disease.
3.Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: analysis in Japanese women.
Nobuhisa YOSHIKAWA ; Hiroaki KAJIYAMA ; Mika MIZUNO ; Kiyosumi SHIBATA ; Michiyasu KAWAI ; Tetsuro NAGASAKA ; Fumitaka KIKKAWA
Journal of Gynecologic Oncology 2014;25(2):118-123
OBJECTIVE: The purpose of this study was to clarify the clinical features of epithelial ovarian carcinoma (EOC) in younger vs. older patients in Japan. METHODS: We collected data on 1,562 patients with EOC treated at multiple institutions in the Tokai Ovarian Tumor Study Group, and analyzed them retrospectively. All patients were divided into 2 groups: group A (< or =40 years old) and group B (>40 years old). The data were analyzed to evaluate prognostic factors and the distribution of features in each group. Patients were subjected to univariate and multivariate analyses to evaluate overall survival (OS). RESULTS: The median follow-up time was 45.1 months (range, 1 to 257 months). Patients in group A had a significantly higher rate of stage I disease (67.3% vs. 42.6%, respectively; p<0.001) and the mucinous type (36.7% vs. 13.5%, respectively; p<0.001) than those in group B. There was a significant difference of OS between the 2 groups (p=0.013). However, upon stratification according to the stage, there were no significant differences in the OS between the 2 groups (group A vs. B: stage I, p=0.533; stage II-IV, p=0.407). Multivariate analysis revealed that younger age was not an independent prognostic factor for OS. CONCLUSION: On the basis of our data, younger patients had a different clinical profile than older patients, particularly regarding the stage of the disease and pathological distribution; however, they showed a similar long-term prognosis, even upon stratification according to the stage.
Asian Continental Ancestry Group*
;
Female
;
Follow-Up Studies
;
Humans
;
Japan
;
Mucins
;
Multivariate Analysis
;
Prognosis
;
Retrospective Studies
4.Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis
Masato YOSHIHARA ; Hiroaki KAJIYAMA ; Satoshi TAMAUCHI ; Shiro SUZUKI ; Kunihiko TAKAHASHI ; Shigeyuki MATSUI ; Fumitaka KIKKAWA
Journal of Gynecologic Oncology 2019;30(6):e102-
OBJECTIVE: The aim of this study was to investigate the clinical characteristics of young patients with stage I clear-cell carcinoma (CCC) and evaluate the prognostic factors and effects of fertility-sparing surgery (FSS) using propensity score (PS) adjustment. METHODS: We conducted a regional multi-institutional study between 1986 and 2017. Among 4,277 patients with ovarian tumor, clinical and pathological data of 103 fertile women with stage I unilateral CCC were collected. We evaluated survival and reproductive outcomes in these patients. Additionally, to analyze the effects of FSS, baseline imbalance between patients with and those without FSS was adjusted with an inverse probability of treatment weighting using PSs involving independent clinical variables. RESULTS: The mean patient age was 39.4 years, and the median follow-up period for surviving patients was 55.6 months. In multivariate analysis, stage IC2/IC3 (vs. IA/IC1) was the only independent prognostic factor for recurrence-free survival (RFS) and overall survival (OS). FSS was not associated with poorer prognosis when compared to the prognosis with non-preserving surgery with regard to both RFS and OS. No statistical difference in survival outcomes between FSS and other approaches was confirmed after PS adjustment. Among patients who underwent FSS, four deliveries with healthy neonates were noted without any gestational complications. CONCLUSION: FSS can be considered in stage I CCC, specifically in stage IA and IC1 patients who strongly desire to have children in the future. Further clinical research is needed to clarify the optimal application of FSS for CCC.
Adenocarcinoma, Clear Cell
;
Child
;
Female
;
Fertility Preservation
;
Follow-Up Studies
;
Humans
;
Infant, Newborn
;
Multivariate Analysis
;
Ovarian Neoplasms
;
Pregnancy
;
Prognosis
;
Propensity Score
5.Novel therapeutic approach for uterine leiomyosarcoma based on transcriptome analysis
Kosuke YOSHIDA ; Akira YOKOI ; Tomoyasu KATO ; Hiroaki KAJIYAMA
Journal of Gynecologic Oncology 2022;33(S1):S1-
Uterine leiomyosarcoma (ULMS) is one of the most aggressive gynecological malignancies. In the past decade, novel therapeutic agents such as trabectedin and pazopanib have been approved, but the prognosis of patients remains unsatisfactory. This study aimed to identify potential therapeutic targets for ULMS based on transcriptome analysis. Archival fresh-frozen tumor tissues of 6 ULMS and three leiomyoma samples were used in this study, and total RNA was extracted. First, transcriptome analysis identified 512 significantly differentially expressed genes, and subsequent pathway analysis using IPA software revealed that the functions of cell cycle-related kinases were significantly activated in ULMS. Moreover, our results were validated using 3 independent Gene Expression Omnibus datasets, including 40 ULMS. Therefore, we considered the kinases as novel therapeutic targets and evaluated the anti-cancer effects of several selective inhibitors against them. Most inhibitors exerted a higher anti-cancer effect than pazopanib in three leiomyosarcoma cell lines. Especially, CHEK1 or PLK1 inhibitors strongly induced cell cycle arrest and cell death, and the IC50s were lower nanomolar concentration. Moreover, the inhibitors suppressed the tumor growth in SK-UT-1 bearing mice models. In conclusion, we revealed the unique gene expression profiles of ULMS. CHEK1 and PLK1 are promising therapeutic targets for ULMS, and therefore, further clinical trials are highly anticipated to improve the prognosis of the patients.
6.Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.
Hiroaki KAJIYAMA ; Kiyosumi SHIBATA ; Mika MIZUNO ; Tomokazu UMEZU ; Shiro SUZUKI ; Ryuichiro SEKIYA ; Kaoru NIIMI ; Hiroko MITSUI ; Eiko YAMAMOTO ; Michiyasu KAWAI ; Tetsuro NAGASAKA ; Fumitaka KIKKAWA
Journal of Gynecologic Oncology 2014;25(1):43-50
OBJECTIVE: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type. METHODS: Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes. RESULTS: The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p<0.001) and PRS (23.0 months vs. 13.0 months, p<0.001) compared to group B. The OS and PRS were similar between the groups in patients with clear cell or mucinous histology. In contrast, among patients with non-clear cell, non-mucinous histologies, the OS and PRS of group A were significantly better than those of group B (OS, p<0.001; PRS, p<0.001). Multivariable analyses revealed that, among patients with non-clear cell, non-mucinous histologies, chemotherapy including taxane and platinum was an independent predictor of favorable survival outcomes. Conversely, in patients with clear cell or mucinous histology, taxane-including platinum-based combination chemotherapy did not improve the OS and PRS compared to a conventional platinum-based regimen which did not include taxanes. CONCLUSION: Since the emergence of taxane plus platinum, the prognosis of patients with recurrent ovarian cancer has improved. However, we here demonstrate that this improvement is limited to patients with non-clear cell, non-mucinous histologies.
Drug Therapy
;
Drug Therapy, Combination
;
Humans
;
Mucins
;
Ovarian Neoplasms*
;
Platinum*
;
Prognosis
;
Taxoids
7.Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma
Kazuhiro SUZUKI ; Akira YOKOI ; Kosuke YOSHIDA ; Tomoyasu KATO ; Takahiro OCHIYA ; Yusuke YAMAMOTO ; Hiroaki KAJIYAMA
Journal of Gynecologic Oncology 2023;34(3):e34-
Objective:
Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian carcinoma with poor prognosis. However, no effective biomarkers have been established for predicting unfavorable events, including recurrence and poor prognoses. Serum microRNAs (miRNAs) have been increasingly reported to be useful in predicting a patient’s condition and have been recognized as a potentially less-invasive source for liquid biopsy in cancer. Therefore, this study aimed to evaluate serum miRNA profiles from patients with OCCC and to establish biomarker for predicting the prognoses.
Methods:
The GSE106817, which included preoperative serum miRNA profiles of patients with ovarian tumors, was used, and clinical information was investigated. In all, 66 patients with OCCC were included, excluding those with other histological subtypes or insufficient prognostic information. Moreover, miRNA profiles of OCCC tissues were also examined.
Results:
The median follow-up period was 64.3 (8.0–153.3) months. Based on multivariable Cox regression analyses and the expression of miRNAs in OCCC tissues, miR-150-3p, miR-3195, and miR-7704 were selected as miRNA candidates associated with both progression-free survival (PFS) and overall survival (OS). Then, the prognostic index was calculated based on expression values of 3 serum miRNAs. Kaplan-Meier survival analysis indicated that the prognostic index was significantly predictive of PFS and OS (p=0.004 and p=0.012, respectively).
Conclusion
Preoperative serum miRNA profiles of miR-150-3p, miR-3195, and miR-7704 can be used to potentially predict the prognosis of patients with OCCC.
8.Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma
Kosuke YOSHIDA ; Nobuhisa YOSHIKAWA ; Akira SHIRAKAWA ; Kaoru NIIMI ; Shiro SUZUKI ; Hiroaki KAJIYAMA ; Fumitaka KIKKAWA
Journal of Gynecologic Oncology 2019;30(6):e85-
OBJECTIVES: There is increasing evidence that systemic inflammatory response (SIR) markers are prognostic factors for various types of cancers. This is the first study to evaluate the usefulness of SIR markers for the prognosis of early-stage ovarian clear-cell carcinoma (OCCC). METHODS: We retrospectively investigated 83 patients diagnosed with stage I–II OCCC who underwent surgery between 2005 and 2017. Initially, receiver operating characteristic curve analysis for overall survival (OS) was used to determine optimal cut-off values for neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Patients were stratified into 2 groups by the cut-off values (NLR=3.26, PLR=160). Univariate and multivariate analyses were performed to elucidate the significance of SIR markers as prognostic factors. RESULTS: In the median follow-up period of 64.1 months, 16 patients experienced recurrence, and nine patients died. The Kaplan-Meier curve showed that OS of the NLR-low group was significantly longer than the NLR-high group (p=0.021). There was no significant difference in progression-free survival between the 2 groups (p=0.668), but the post-recurrence survival of the NLR-low group was significantly longer than the NLR-high group (p=0.019). Furthermore, multivariate analysis showed that increase in NLR is a significant independent prognostic factor for poor prognosis (hazard ratio=7.437, p=0.017). There was no significant difference between PLR-low and PLR-high group. CONCLUSION: Results suggest that NLR can be a significant independent prognostic factor for early-stage OCCC.
Adenocarcinoma, Clear Cell
;
Biomarkers
;
Disease-Free Survival
;
Follow-Up Studies
;
Humans
;
Multivariate Analysis
;
Prognosis
;
Recurrence
;
Retrospective Studies
;
ROC Curve
9.Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study
Yoshiki IKEDA ; Masato YOSHIHARA ; Satoshi TAMAUCHI ; Akira YOKOI ; Nobuhisa YOSHIKAWA ; Hiroaki KAJIYAMA
Journal of Gynecologic Oncology 2022;33(4):e40-
Objective:
The survival benefits of retroperitoneal lymphadenectomy (RLNA) for epithelial ovarian cancer (EOC) remain controversial because clinical behaviors differ among subtypes. The purpose of the present study was to clarify whether RLNA increases the survival rate of advanced high-grade serous carcinoma (HGSC).
Methods:
This was a retrospective cohort analysis of 3,227 patients with EOC treated between 1986 and 2017 at 14 institutions. Among them, 335 patients with stage IIB-IV HGSC who underwent optimal cytoreduction (residual tumor of <1 cm) were included. Patients were divided into the RLNA group (n=170) and non-RLNA group (n=165). All pathological slides were assessed based on a central pathological review. Oncologic outcomes were compared between the two groups in the original and weighted cohorts adjusted with the inverse probability of treatment weighting.
Results:
The median observation period was 49.8 (0.5–241.5) months. Overall, 219 (65%) out of 335 patients had recurrence or progression, while 146 (44%) died of the disease. In the original cohort, RLNA was a significant prognostic factor for longer progression-free survival (PFS) (hazard ratio [HR]=0.741; 95% confidence interval [CI]=0.558–0.985) and overall survival (OS) (HR=0.652; 95% CI=0.459–0.927). In the weighted cohort in which all variables were well balanced as standardized differences decreased, RLNA was also a significant prognostic factor for more favorable oncologic outcomes (PFS, adjusted HR=0.742; 95% CI=0.613–0.899) and OS, adjusted HR=0.620; 95% CI=0.488–0.787).
Conclusion
The present study demonstrated that RLNA for stage III-IV HGSC with no residual tumor after primary debulking surgery contributed to better oncologic outcomes.
10.Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis
Masato YOSHIHARA ; Satoshi TAMAUCHI ; Shohei IYOSHI ; Kazuhisa KITAMI ; Kaname UNO ; Kazumasa MOGI ; Hiroaki KAJIYAMA
Journal of Gynecologic Oncology 2021;32(5):e66-
Objective:
The aim of the present study was to examine the effects of incomplete surgery and adjuvant chemotherapy on the prognosis of patients with intraoperative rupture of capsulated stage I epithelial ovarian cancer (OvCa).
Methods:
A regional retrospective study was conducted between 1986 and 2019. Among 4,730 patients with malignant ovarian tumors, 534 women with International Federation of Gynecology and Obstetrics stage IA and IC1 epithelial OvCa were eligible. Differences in survival outcomes were examined between patients with stage IA and IC1 tumors and the effects of uterine preservation, complete-staging lymphadenectomy, and adjuvant chemotherapy were investigated by an in-depth subgroup analysis. To analyze therapeutic effects, baseline imbalances were adjusted using propensity score (PS).
Results:
The prognosis of patients with stage IC1 tumors was worse than those with stage IA. Surgical spill did not affect the site of recurrence. In the PS-adjusted subgroup analysis, uterine preservation (hazard ratio [HR]=1.669; 95% confidence interval [CI]=1.052–2.744), incomplete-staging lymphadenectomy (HR=1.689; 95% CI=1.211–2.355), and the omission of adjuvant chemotherapy (HR=3.729; 95% CI=2.090–6.653) significantly increased the HR of recurrence for patients with stage IC1 tumors compared to those with stage IA tumors. Adjuvant chemotherapy decreased the impact of rupture with uterine preservation (HR=0.159; 95% CI=0.230–1.168) or incomplete-staging lymphadenectomy (HR=0.987; 95% CI=0.638–1.527).
Conclusion
The present results suggest intraoperative rupture of capsulated stage I epithelial OvCa is associated with a poor prognosis. When chemotherapy is given for patients receiving incomplete surgery, there is no longer an increased risk of recurrence observed with the rupture.